"Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis"
Project Number5R01CA272466-02
Former Number1R01CA272466-01
Contact PI/Project LeaderNOWAK, DAWID GRZEGORZ
Awardee OrganizationWEILL MEDICAL COLL OF CORNELL UNIV
Description
Abstract Text
PROJECT SUMMARY / ABSTRACT
On average, a man dies from PCa every 16 minutes, mainly due to development of secondary malignant
growths outside of the primary cancer site, known as metastases. The cornerstone of PCa treatment is
androgen deprivation therapy (ADT). ADT temporarily halts PCa, but leads to resistance in nearly all cases,
resulting in castration-resistant PC (CRPC). CRPC then undergoes further evolution of metastatic subclones
and results in incurable disease. Research techniques revealing resistance mechanisms and clonal evolution
of metastatic PCa are lacking due to the limited capacity of current animal models to mimic PCa evolution in its
native microenvironment as well as inefficient methods for tracing subclonal evolution.
Therefore, we developed EvoCaP (!Evolution in Cancer of the Prostate”), a mouse model of endogenous
metastasis that recapitulates human PCa genetically, by using PTEN/TP53 co-deletions enriched in metastatic
patients, and phenotypically, by focal initiation of primary disease progressing to bones, lungs, lymph nodes
and liver metastases. Our model uses a lentiviral platform - LV.CreBC10 carrying: (1) Cre (Pten/Trp53 co-
deletions; activation of Cas9, fluorescence and luminescence markers); (2) Barcode with ten sites for marking
by Cas9 (BC10); (3) RNA guide specifically marking BC10; and (4) guide or short hairpin RNA for testing
metastatic drivers. Luminescence (FLuc) permits continuous tracking of disease progression and fluorescence
(eGFP) allows for specific sorting of cancer cells. BC10 represents a synthetic array of on-target sites, in order
of decreasing activity, for the RNA guide that attracts Cas9 to generate subsequently specific edits. To
streamline barcode analysis, we have established an R package - EvoTraceR. This comprehensive system
enables: (1) the profiling of cancer cells based on shared mutational patterns in primary and metastasis; and
(2) the building of phylogenetic trees to track evolution toward metastases in a robust and flexible way.
Our central hypothesis is that differences in distinct molecular and phenotypical clonal architectures will be
precisely detected between primary and metastatic sites depending on therapy status, enabling the inhibition of
metastasis and/or resistance promoting genes and pathways. Our analyses will establish and mechanistically
validate drivers of metastatic clonal expansion caused by Pten/Tp53-loss (basal) and also investigate how
evolutionary pressure from therapy (ADT), applied at different stages of PCa, leads to the emergence of
resistant clones. We will then use Cas9/guide (g)RNA and inducible short hairpins to target genes altered in
those expanding clones to identify drivers of both treatment-naive and treatment-induced PCa metastasis.
EvoCaP can feasibly track molecular evolution and validate targets for drug development, which may lead to
identification of novel metastatic driver genes and pathways. Thus, therapies could be applied in: (1) primary
diseases for early detection and interruption of metastases development; and (2) already existing metastases.
Importantly, technologies developed in this project can also be applied to other types of metastatic cancers.
Public Health Relevance Statement
PROJECT NARRATIVE
The proposed project seeks to advance public health by improving the very poor survival rate of patients with
prostate cancer (PCa) due to the presence of metastases and no available curative therapies. Our research
will identify alterations causing PCa to spread to other tissues by tracking the metastatic clones as they
develop using our new model system, EvoCaP, both in the presence and absence of standard therapy. By
identifying genes and pathways that cause PCa to spread and colonize different organs, our project is
designed to find new, vital drug targets previously missed by traditional methods of identification, to treat
advanced forms of metastatic PCa.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccountingAddressAffectAftercareAnimal ModelAnimalsArchitectureAutomobile DrivingBar CodesBiological ModelsCancer PrognosisCancer RelapseCastrationCellsCessation of lifeClonal EvolutionClonal ExpansionComputer ModelsComputing MethodologiesConsumptionDataDevelopmentDiseaseDisease ProgressionDisseminated Malignant NeoplasmDrug TargetingEarly DiagnosisEvolutionFluorescenceGene Expression ProfilingGenesGenomicsGoalsGrowthGuide RNAHeritabilityHormonesHumanImmune systemInterruptionInterventionKnowledgeLiverLungMYC geneMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMapsMetastatic Neoplasm to the LiverMetastatic Prostate CancerMethodsModelingMolecularMolecular EvolutionMutationNeoplasm MetastasisOrganOutcomePTEN genePathway interactionsPatientsPatternPhasePhenotypePhylogenetic AnalysisPhysiologicalPopulationPrimary NeoplasmProbabilityProcessProstateProstate Cancer therapyProto-OncogenesPublic HealthRB1 geneRNAResearchResearch TechnicsResistanceSiteSomatic CellSortingSurvival RateSystemTP53 geneTechnologyTestingTherapeuticTimeTissuesTreesTumor Suppressor Proteinsandrogen deprivation therapyanimal breedingbonecancer cellcancer sitecancer therapycurative treatmentsdesigndisorder controldrug developmentflexibilitygenetic signatureimprovedknock-downluminescencelymph nodesmanmenmigrationmortalitymouse modelnovelpostnatalpressurepreventprostate cancer metastasisprostate cancer modelresistance mechanismsmall hairpin RNAtargeted cancer therapytumortumor heterogeneity
No Sub Projects information available for 5R01CA272466-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA272466-02
Patents
No Patents information available for 5R01CA272466-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA272466-02
Clinical Studies
No Clinical Studies information available for 5R01CA272466-02
News and More
Related News Releases
No news release information available for 5R01CA272466-02
History
No Historical information available for 5R01CA272466-02
Similar Projects
No Similar Projects information available for 5R01CA272466-02